Trimethoprim-sulfamethoxazole-induced stevens-johnson syndrome: A case report

Journal of the American Podiatric Medical Association

Volumn 100, Issue 4, 2010, Pages 299-303

  Langlois, R Michael ^a   Derk, Francis ^b   Belczyk, Ronald ^a   Zgonis, Thomas ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78650294809     PISSN: 87507315     EISSN: None     Source Type: Journal    
DOI: 10.7547/1000299     Document Type: Article

References (11)

1. RAOFI S, SHAPPERT SM: Medication therapy in ambulatory medical care: United States, 2003-04. Vital Health Stat13 163: 1, 2006.
2. MA J, STAFFORD RS, COCKBURN IM, ET AL: A statistical analysis of the magnitude and composition of drug promotion in the United States in 1998. Clin Ther 25: 1503, 2003.
3. SHEHAB N, PATEL PR, SRINIVASAN A, ET AL: Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis 47: 735, 2008.
4. SYLVIA LM: "Drug Allergy and Pseudoallergy," in Drug-Induced Diseases: Prevention, Detection, and Management, Vol 1, ed by JE Tisdale, DA Miller, p 27, American Society of Health-System Pharmacists, Bethesda, MD, 2005.
5. GARCIA-DOVAL I, LECLEACH L, BOCQUET H, ET AL: Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of drugs decrease the risk of death? Arch Dermatol 136: 323, 2000.
6. REVUZ J, PENSO D, ROUJEAU JC, ET AL: Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch Dermatol 123: 1160, 1987.
7. PALMIERI TL, GREENHALGH DG, SAFFLE JR, ET AL: A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil 23: 87, 2002.
8. CHIA FL, LEONG KP: Severe cutaneous adverse reactions to drugs. Curr Opin Allergy Clin Immunol 7: 304, 2007.
9. HALEVY S, GHISLAIN PD, MOCKENHAUPT M, ET AL: Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 58: 25, 2007.
10. MOCKENHAUPT M, KELLY JP, KAUFMAN D, ET AL: The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with anti-inflammatory drugs: a multinational perspective. J Rheumatol 30: 2234, 2003.
11. ROUJEAU JC, KELLY JP, NALDI L, ET AL: Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 333: 1600, 1995.